Profile data is unavailable for this security.
About the company
Revolution Medicines, Inc. is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers. The Company’s research and development pipeline comprises RAS(ON) inhibitors that bind directly to RAS variants, which it refers to as RAS(ON) Inhibitors, and RAS companion inhibitors that target key nodes in the RAS pathway or associated pathways, which it refers to as RAS Companion Inhibitors. Its RAS(ON) Inhibitors are designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or in combination with RAS Companion Inhibitors or other therapeutic agents. Its RAS Companion Inhibitors are designed primarily for combination treatment strategies centered on its RAS(ON) Inhibitors. The Company’s RAS(ON) Inhibitors RMC-6236 RMC-6291 and RMC-9805 are in clinical development. RMC-6236, its RASMULTI(ON) inhibitor, is designed as a potent, oral, RAS-selective tri-complex inhibitor of multiple RAS(ON) variants, including cancer drivers.
- Revenue in USD (TTM)11.58m
- Net income in USD-436.37m
- Incorporated2014
- Employees378.00
- LocationRevolution Medicines Inc700 Saginaw DrREDWOOD CITY 94063-4752United StatesUSA
- Phone+1 (415) 766-3638
- Fax+1 (302) 636-5454
- Websitehttps://www.revmed.com/
More ▼
Mergers & acquisitions
| Acquired company | RVMD:NSQ since announced | Transaction value |
|---|---|---|
| EQRX Inc | 36.50% | 1.58bn |
Data delayed at least 15 minutes, as of Apr 18 2024 21:00 BST.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Madrigal Pharmaceuticals Inc | 0.00 | -373.63m | 4.79bn | 376.00 | -- | 10.90 | -- | -- | -19.93 | -19.93 | 0.00 | 20.39 | 0.00 | -- | -- | 0.00 | -74.49 | -62.09 | -97.21 | -74.81 | -- | -- | -- | -- | -- | -- | 0.2217 | -- | -- | -- | -26.50 | -- | 132.01 | -- |
| Halozyme Therapeutics, Inc. | 829.25m | 281.59m | 4.83bn | 373.00 | 17.93 | 57.19 | 13.20 | 5.79 | 2.11 | 2.11 | 6.18 | 0.6611 | 0.464 | 1.69 | 3.56 | 2,223,199.00 | 15.75 | 18.22 | 16.90 | 21.97 | 76.80 | 79.05 | 33.96 | 39.36 | 5.50 | 139.09 | 0.9471 | 0.00 | 25.62 | 40.43 | 39.31 | -- | 26.82 | -- |
| Krystal Biotech Inc | 50.70m | 10.93m | 4.84bn | 229.00 | 1,852.98 | 5.95 | 277.15 | 92.22 | 0.0885 | 0.0885 | 1.84 | 27.58 | 0.0737 | -- | -- | 221,393.00 | 1.59 | -11.50 | 1.66 | -12.01 | 93.90 | -- | 21.56 | -492.85 | 17.55 | -- | 0.00 | -- | -- | -- | 107.81 | -- | 39.49 | -- |
| Blueprint Medicines Corp | 249.38m | -506.98m | 5.41bn | 655.00 | -- | 41.62 | -- | 21.83 | -8.37 | -8.37 | 4.12 | 2.14 | 0.2079 | 0.3354 | 6.23 | 380,732.80 | -42.26 | -29.92 | -50.67 | -34.06 | 96.58 | -- | -203.30 | -116.65 | 3.66 | -25.88 | 0.6465 | -- | 22.22 | 41.14 | 9.06 | -- | 4.85 | -- |
| Apellis Pharmaceuticals Inc | 396.59m | -528.63m | 5.79bn | 702.00 | -- | 29.20 | -- | 14.45 | -4.48 | -4.48 | 3.34 | 1.63 | 0.5121 | 0.5042 | 3.70 | 564,944.40 | -68.26 | -73.88 | -93.25 | -90.03 | 85.25 | -- | -133.29 | -326.49 | 2.50 | -59.78 | 0.6775 | -- | 425.83 | -- | 18.94 | -- | -- | -- |
| Ionis Pharmaceuticals Inc | 787.65m | -366.29m | 5.96bn | 927.00 | -- | 15.23 | -- | 7.55 | -2.56 | -2.56 | 5.50 | 2.68 | 0.2852 | 0.362 | 12.77 | 849,673.10 | -13.26 | -6.30 | -15.38 | -7.44 | 98.84 | 98.75 | -46.50 | -21.23 | 5.83 | -- | 0.7671 | -- | 34.10 | 5.60 | -35.80 | -- | 11.83 | -- |
| Revolution Medicines Inc | 11.58m | -436.37m | 6.06bn | 378.00 | -- | 3.23 | -- | 509.57 | -3.77 | -3.77 | 0.1024 | 11.09 | 0.0081 | -- | 3.91 | 30,634.92 | -30.37 | -29.76 | -32.71 | -32.59 | -- | -- | -3,768.28 | -606.93 | -- | -- | 0.00 | -- | -67.27 | -10.50 | -75.46 | -- | 38.82 | -- |
| Elanco Animal Health Inc | 4.42bn | -1.23bn | 6.61bn | 9.30k | -- | 1.07 | -- | 1.51 | -2.50 | -2.50 | 8.96 | 12.63 | 0.2959 | 1.18 | 5.39 | 474,946.30 | -8.25 | -3.27 | -9.15 | -3.65 | 56.28 | 54.28 | -27.87 | -11.53 | 1.35 | 1.18 | 0.4813 | -- | 0.136 | 7.57 | -1,478.21 | -- | 2.74 | -- |
| Jazz Pharmaceuticals PLC | 3.83bn | 414.83m | 6.68bn | 2.80k | 17.87 | 1.82 | 6.45 | 1.78 | 6.12 | 6.12 | 53.20 | 60.03 | 0.345 | 0.6645 | 5.65 | 1,369,359.00 | 3.76 | 1.48 | 4.23 | 1.62 | 88.64 | 88.79 | 10.90 | 4.26 | 1.85 | 2.06 | 0.6048 | 0.00 | 4.78 | 15.19 | 285.14 | -1.49 | -20.04 | -- |
| Vaxcyte Inc | 0.00 | -402.27m | 6.77bn | 254.00 | -- | 4.66 | -- | -- | -4.07 | -4.07 | 0.00 | 13.01 | 0.00 | -- | -- | 0.00 | -33.33 | -34.22 | -36.11 | -37.21 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -80.00 | -- | 107.28 | -- |
| Exelixis Inc | 1.83bn | 207.77m | 6.93bn | 1.31k | 34.75 | 3.01 | 29.20 | 3.73 | 0.6472 | 0.6472 | 5.69 | 7.48 | 0.6087 | 2.87 | 8.09 | 1,397,105.00 | 6.91 | 8.86 | 7.85 | 9.91 | 96.04 | 96.30 | 11.35 | 15.43 | 3.30 | -- | 0.00 | 0.00 | 13.60 | 16.47 | 13.98 | -21.34 | 3.98 | -- |
| Cytokinetics, Inc. | 7.53m | -526.24m | 7.10bn | 423.00 | -- | -- | -- | 930.49 | -5.45 | -5.45 | 0.078 | -3.80 | 0.0082 | -- | 10.53 | 17,801.42 | -57.23 | -43.14 | -63.72 | -47.22 | -- | -- | -6,988.63 | -540.47 | -- | -16.52 | 2.66 | -- | -92.04 | -24.89 | -35.30 | -- | 9.76 | -- |
| Bellring Brands Inc | 1.73bn | 165.20m | 7.11bn | 420.00 | 43.81 | -- | 33.70 | 4.10 | 1.24 | 1.24 | 12.99 | -2.19 | 2.39 | 5.89 | 9.62 | 4,129,762.00 | 22.78 | 18.89 | 29.01 | -- | 32.08 | 32.44 | 9.52 | 10.10 | 1.71 | 4.39 | 1.53 | 0.00 | 21.53 | 15.03 | 101.09 | 13.80 | -18.48 | -- |
| Viking Therapeutics Inc | 0.00 | -85.90m | 7.33bn | 27.00 | -- | 18.58 | -- | -- | -0.9153 | -0.9153 | 0.00 | 3.48 | 0.00 | -- | -- | 0.00 | -31.99 | -21.91 | -34.64 | -23.04 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -24.73 | -- | -- | -- |
Data as of Apr 18 2024. Currency figures normalised to Revolution Medicines Inc's reporting currency: US Dollar USD
48.16%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Wellington Management Co. LLPas of 31 Dec 2023 | 14.88m | 9.04% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 14.30m | 8.68% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 10.70m | 6.50% |
| Farallon Capital Management LLCas of 31 Dec 2023 | 6.74m | 4.09% |
| SSgA Funds Management, Inc.as of 31 Dec 2023 | 6.25m | 3.80% |
| BVF Partners LPas of 31 Dec 2023 | 5.98m | 3.63% |
| Casdin Capital LLCas of 31 Dec 2023 | 5.71m | 3.47% |
| Baker Bros. Advisors LPas of 31 Dec 2023 | 5.15m | 3.13% |
| Bellevue Asset Management AGas of 31 Dec 2023 | 5.09m | 3.09% |
| T. Rowe Price Associates, Inc. (Investment Management)as of 31 Dec 2023 | 4.51m | 2.74% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
